Pharmaceutical CRDMO Services Market Size is valued at USD 114.8 billion in 2023 and is predicted to reach USD 266.7 billion by the year 2031 at an 11.3% CAGR during the forecast period for 2024-2031.
Pharmaceutical Contract Research, Development, and Manufacturing Organization (CRDMO) services provide a comprehensive and unified solution for drug development, encompassing research, development, and manufacturing. These services encompass the entire spectrum of activities, ranging from initial drug exploration and clinical experiments to the mass production of medications. Contract Research and Development Organizations (CRDMOs) play a crucial role in refining the entire drug development process, cutting down expenses, and enhancing productivity. As a result, they are indispensable collaborators for companies seeking to introduce novel medications to the market.
The growing population is expected to create significant healthcare opportunities in the forecast period. The increasing requirement for pharmaceutical products and the need for efficient manufacturing and development processes make CDMOs vital for managing innovation and development programs under one roof. CDMOs enable pharmaceutical companies to outsource drug development and peoduction in a timely and cost-effective manner. Additionally, increased investment in research and development by the pharmaceutical industry will drive the growth of the CDMO sector.
The Pharmaceutical CRDMO Service Market is segmented by type and application. By type, services include Small Molecular CRDMO, Middle Molecular CRDMO, and Large Molecular CRDMO services, each catering to different scales and complexities of drug development and manufacturing. By application, CRDMOs specialize in various therapeutic areas such as Oncology, Central Nervous System (CNS) disorders, Cardiovascular diseases, Infectious Diseases, Hematology, and Vaccine development.
The oncology category is predicted to hold a major share of the global Pharmaceutical CRDMO Services market. There is a significant and growing demand for oncology drugs globally due to increasing cancer incidence and prevalence. This drives pharmaceutical companies to focus heavily on oncology drug development and manufacturing. Oncology drugs often require specialized manufacturing processes and expertise due to their complexity, including biologics, cytotoxics, and targeted therapies. CRDMOs specializing in oncology can offer the necessary capabilities and infrastructure.
The Small Molecule CRDMO Services segment commands the largest share in the Pharmaceutical CRDMO Service Market for several key reasons. Firstly, small molecule drugs constitute a substantial portion of the pharmaceutical market, encompassing generics and newly developed chemical entities, which drives the demand for outsourcing their development and production. CRDMOs specializing in small molecules typically possess well-established expertise in organic synthesis, process chemistry, and formulation development, supported by a robust infrastructure for large-scale manufacturing. This specialization enables cost-effective operations, leveraging lower labour and operational costs in regions like Asia-Pacific. Moreover, these CRDMOs offer flexibility in manufacturing schedules and faster time-to-market, which is crucial for meeting regulatory timelines and market demands. Their experience in navigating complex global regulatory frameworks ensures compliance with stringent quality standards, further reinforcing their leadership in this competitive market segment.
The North American Pharmaceutical CRDMO Services market is expected to register the highest market share. The market is estimated to get bigger due to the expansion of manufacturing units within the pharmaceutical industry. The increasing overall geriatric population in the region is expected to drive higher demand for these services from the healthcare sector. Additionally, advancements in pharmaceutical technology will boost the growth of the contract research, development & manufacturing organization market. Furthermore, the well-established healthcare infrastructure and favourable government policies aimed at improving healthcare services contribute to the market's expansion in North America. In addition, Asia Pacific is likely to grow rapidly in the global Pharmaceutical CRDMO Services market. CRDMOs in APAC are adopting advanced technologies and processes for drug development and manufacturing. This includes capabilities in biologics, generics, and speciality pharmaceuticals, driving their attractiveness to global pharmaceutical companies.
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 114.8 Bn |
|
Revenue Forecast In 2031 |
USD 266.7 Bn |
|
Growth Rate CAGR |
CAGR of 11.3% from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Type and Application. |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
BioDuro-Sundia, Sai Life Sciences, Icosagen, WuXi Biologics, WuXi AppTec, Esco Aster, Jubilant Biosys, Syngene International, Chemveda, Ardena Holding, Eurofins, Jiangsu HUAYI Technology Co., Ltd. |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Pharmaceutical CRDMO Service Market Snapshot
Chapter 4. Global Pharmaceutical CRDMO Service Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Type Estimates & Trend Analysis
5.1. by Type & Market Share, 2019 & 2031
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Type:
5.2.1. Small Molecule CRDMO Service
5.2.2. Middle Molecule CRDMO Service
5.2.3. Large Molecule CRDMO Service
Chapter 6. Market Segmentation 2: by Application Estimates & Trend Analysis
6.1. by Application & Market Share, 2019 & 2031
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2019 to 2031 for the following by Application:
6.2.1. Oncology
6.2.2. Infectious Disease
6.2.3. Neurology
6.2.4. Immunology
6.2.5. Hematology
6.2.6. Vaccine
Chapter 7. Pharmaceutical CRDMO Service Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.1.2. North America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.1.3. North America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.2. Europe
7.2.1. Europe Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.2.2. Europe Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.2.3. Europe Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.3. Asia Pacific
7.3.1. Asia Pacific Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.3.2. Asia Pacific Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.3.3. Asia Pacific Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.4. Latin America
7.4.1. Latin America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.4.2. Latin America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.4.3. Latin America Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
7.5. Middle East & Africa
7.5.1. Middle East & Africa Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Type, 2023-2031
7.5.2. Middle East & Africa Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by Application, 2023-2031
7.5.3. Middle East & Africa Pharmaceutical CRDMO Service Market Revenue (US$ Million) Estimates and Forecasts by country, 2023-2031
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. BioDuro-Sundia
8.2.2. Sai Life Sciences
8.2.3. Icosagen
8.2.4. WuXi Biologics
8.2.5. WuXi AppTec
8.2.6. Esco Aster
8.2.7. Jubilant Biosys
8.2.8. Syngene International
8.2.9. Chemveda
8.2.10. Ardena Holding
8.2.11. Eurofins
8.2.12. Jiangsu HUAYI Technology Co., Ltd.
Pharmaceutical CRDMO Market By Type -
Pharmaceutical CRDMO Market By Application-
Pharmaceutical CRDMO Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
